Johnson & Johnson has increased its dividend for the 64th consecutive year, paying $1.34 per share quarterly, reflecting a 3.1% raise. The company maintains a strong financial position with a payout ratio near 48%, supported by robust operating cash flow of $24.53 billion in 2025 against a $12.38 billion dividend payout. Despite competitive pressures on its drug STELARA, JNJ's innovative medicines continue to grow, with sales reaching $25.3 billion in Q2 2026 and adjusted EPS guidance raised for 2026. This steady growth and strong cash flow underpin JNJ's commitment to returning capital to shareholders, making its dividend attractive for income-focused investors.
Johnson & Johnson is rated HOLD for the next 6-12 months due to balanced risks. Its drug portfolio growth offsets losses from Stelara, but the MedTech segment remains a weak growth driver. The company's valuation is above historical averages, reflect...
Procter & Gamble (P&G) and Johnson & Johnson (J&J) both recently increased their long-standing dividends, but P&G's dividend appears more stable due to no planned corporate changes. J&J is preparing a mid-2027 spinoff of its DePuy Synthes unit, which...
JPMorgan's JEPI ETF has seen its monthly payouts decrease throughout 2026 despite the S&P 500 rallying strongly. JEPI's strategy of selling option premiums on low-volatility stocks limits upside gains, making it underperform in a calm, rising market....
The Health Care Select Sector SPDR Fund (XLV) offers broad healthcare exposure but delivers a low dividend yield around 1.5% due to its cap-weighted structure favoring large, lower-yield stocks like Eli Lilly. Directly owning top XLV holdings AbbVie,...
Despite two major recessions in the past two decades, four healthcare companies—Johnson & Johnson, Abbott Laboratories, Medtronic, and Becton Dickinson—consistently raised their dividends each quarter. Their strong cash flows and inelastic demand for...
